ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Untangling neuropathic pain: pathophysiological insights and future directions for targeted therapy.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary objective of this study is to investigate the intricate underlying mechanisms of neuropathic pain using a multifaceted framework which includes cellular, molecular, and systems-level perspectives as well as molecular targets for establishing the customised pain relief strategies to improve clinical outcomes. In order to provide an in-depth understanding of neuropathic pain processes as well as treatment approaches, this review addresses research in molecular biology, neurophysiology and molecular mechanisms including neurotransmitter modifications, ion channel failure, and gene expression changes along with current developments in emerging pharmacological and non-pharmacological therapies, relying on peer-reviewed studies, experimental research, and clinical trials. The review reveals that neuropathic pain is driven by several distinct pathways rather than a single pathological process. Significant findings demonstrate that altered ion channel activity, neurotransmitter dysregulation, inflammation, microglial activation and oxidative stress contribute to pain persistence. Current treatments, including antidepressants and opioids, provide limited relief and can cause side effects, whereas non-pharmacological methods offer supportive advantages. Neuropathic pain is a complex condition influenced by neurobiological changes at molecular, cellular, and systemic levels. Understanding of these pathways is essential for creating personalised medicines that go beyond conventional symptomatic relief. Enhancing pain management and improving patient quality of life may be possible with new molecular targets and integrated therapy approaches. In order to reduce the worldwide burden of chronic neuropathic pain, future research must concentrate on transforming molecular findings into practicable therapeutic approaches.
Indexed as
Identifiers
42217042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.